Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.50 |
| ▸ | POLB | P06746 | 3/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | APEX1 | P27695 | 1/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.48 |
| ▸ | BLM | P54132 | 2/20 | 0.48 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.48 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | HTR2A | P28223 | 1/20 | 0.48 |
| ▸ | HRH1 | P35367 | 1/20 | 0.48 |
| ▸ | SCN1A | P35498 | 1/20 | 0.48 |
| ▸ | SCN4A | P35499 | 1/20 | 0.48 |
| ▸ | CACNA1D | Q01668 | 1/20 | 0.48 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.48 |
| ▸ | CACNA1S | Q13698 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Doxenitoin SCHEMBL27893787 | 0.98 | KMT2A (0.49) | KMT2APOLBTDP1MEN1CYP1A2 | |
| SCHEMBL11884797 | 0.82 | CYP2C9 (0.47) | KMT2APOLBTDP1MEN1CYP1A2 | |
| SCHEMBL18622047 | 0.71 | MMP2 (0.64) | KMT2APOLBTDP1MEN1CYP1A2 | |
| SCHEMBL20304019 | 0.69 | TSHR (0.47) | KMT2APOLBTDP1MEN1CYP1A2 | |
| Primidone SCHEMBL34221 | 0.67 | KMT2A (1.00) | KMT2APOLBTDP1MEN1CYP1A2 | |
| SCHEMBL20304196 | 0.67 | TSHR (0.45) | KMT2APOLBTDP1MEN1CYP1A2 | |
| SCHEMBL9666695 | 0.67 | OPRM1 (0.40) | KMT2APOLBTDP1MEN1CYP1A2 | |
| Phenytoin SCHEMBL3440 | 0.65 | CYP2C9 (1.00) | CYP2C9BLMPMP22CACNA1FALDH1A1 | |
| Phenytoin SCHEMBL5499612 | 0.65 | CYP2C9 (1.00) | CYP2C9BLMPMP22CACNA1FALDH1A1 | |
| SCHEMBL11147883 | 0.65 | AKR1B1 (0.61) | TDP1TSHRALDH1A1AKR1B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 583 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12464303-B2 | Apparatus and method for providing individual sound zones | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. (DE) | 2025-11-04 | — | — | US | claimed |
| CN-120065364-A | Maneuvering GEO satellite searching method based on optical orbit measurement data | 西北工业大学 | 2025-05-30 | — | — | CN | claimed |
| CN-119316860-B | 5G perception Doppler diffusion clutter suppression method based on subcarrier domain and airspace combined dimensionality reduction processing | 哈尔滨工业大学 | 2025-05-16 | — | — | CN | claimed |
| EP-4551520-A2 | HIGH-ENERGY ALL-SOLID-STATE LITHIUM BATTERIES | Yeda Research and Development Co. Ltd (IL) | 2025-05-14 | — | — | EP | claimed |
| CN-119595909-A | Method for detecting bacterial endotoxin of natural killer cell suspension | 哈尔滨北科健康科技有限公司 | 2025-03-11 | — | — | CN | claimed |
| CN-119523452-A | Heartbeat waveform reconstruction method based on MIMO millimeter wave radar signals | 南京邮电大学 | 2025-02-28 | — | — | CN | claimed |
| CN-119316860-A | 5G perception Doppler diffusion clutter suppression method based on subcarrier domain and airspace combined dimensionality reduction processing | 哈尔滨工业大学 | 2025-01-14 | — | — | CN | claimed |
| CN-118784188-A | Communication method and communication device | 华为技术有限公司 | 2024-10-15 | — | — | CN | claimed |
| WO-2024208287-A1 | COMMUNICATION METHOD AND COMMUNICATION APPARATUS | 华为技术有限公司 | 2024-10-10 | — | — | WO | claimed |
| CN-118534252-A | Power grid broadband oscillation positioning early warning system and method | 中国南方电网有限责任公司 | 2024-08-23 | — | — | CN | claimed |
| EP-2026788-A1 | THERAPEUTIC COMBINATION FOR PAINFUL MEDICAL CONDITIONS | SCHWARZ PHARMA AG (DE) | 2009-02-25 | — | — | EP | claimed |
| CN-101330905-A | Freeze-drying process and products obtained thereby | SCIDOSE LLC (US) | 2008-12-24 | — | — | CN | claimed |
| EP-1954244-A1 | LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY | Scidose, Llc (US) | 2008-08-13 | — | — | EP | claimed |
| WO-2007141018-A1 | THERAPEUTIC COMBINATION FOR PAINFUL MEDICAL CONDITIONS | SCHWARZ PHARMA AG (DE) | 2007-12-13 | — | — | WO | claimed |
| WO-2007061529-A1 | LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY | SCIDOSE LLC. (US) | 2007-05-31 | — | — | WO | claimed |
| US-20070116729-A1 | Lyophilization process and products obtained thereby | SCIDOSE LLC | 2007-05-24 | — | — | US | claimed |
| US-20070043120-A1 | Therapeutic combination for painful medical conditions | UCB PHARMA GMBH (DE) | 2007-02-22 | — | — | US | claimed |
| US-20070042969-A1 | Combination therapy for pain in painful diabetic neuropathy | SRZ PROPERTIES, INC. (US) | 2007-02-22 | — | — | US | claimed |
| EP-1073470-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2001-02-07 | — | — | EP | claimed |
| WO-2000048636-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2000-08-24 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070042969-A1 | Combination therapy for pain in painful diabetic neuropathy | GRIN2B, GRIN2A, GRIN3A | KMT2A 617/4885POLB 2633/4885TDP1 2854/4885 |
| US-20070043120-A1 | Therapeutic combination for painful medical conditions | PDE1B, CA2, CACNA1S | KMT2A 1606/4885POLB 4249/4885TDP1 2352/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.